Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart

(City of Hope) Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the FDA, reports a City of Hope-led study. Published in The Lancet Oncology, the study is the first to show the benefit of tivozanib for patients with renal cell carcinoma (kidney cancer) who had received two or more previous therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news